Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats

European Journal of Heart Failure

Volumn 14, Issue 2, 2012, Pages 193-201

  Daniels, Anneleen ^a   Linz, Dominik ^a   Van Bilsen, Marc ^a   Rütten, Hartmut ^b   Sadowski, Thorsten ^b   Ruf, Sven ^b   Juretschke, Hans Paul ^b   Neumann Haefelin, Claudia ^b   Munts, Chantal ^a   Van Der Vusse, Ger J ^a   Van Nieuwenhoven, Frans A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Cardiac fibrosis; Cardiac function; Diabetes mellitus; Myocardial remodelling

Indexed keywords

ALBUMIN; COLLAGEN; GLYCOSYLATED HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART WEIGHT; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIASTOLE; MALE; RATS; RATS, ZUCKER; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84856193298     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr166     Document Type: Article

References (35)

1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
2. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543-567. (Pubitemid 39096070)
3. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy-fact or fiction? Herz 2011;36:102-115.
4. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98:596-605.
5. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115: 3213-3223. (Pubitemid 47012236)
6. Daniels A, van Bilsen M, Janssen BJ, Brouns AE, Cleutjens JP, Roemen TH, Schaart G, van der Velden J, van der Vusse GJ, van Nieuwenhoven FA. Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxf) 2010;200:11-22.
7. Schafer S, Huber J, Wihler C, Rutten H, Busch AE, Linz W. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(1)-(carboxymethyl) lysine. Eur J Heart Fail 2006;8:2-6. (Pubitemid 43012094)
8. Radovits T, Korkmaz S, Loganathan S, Barnucz E, Bomicke T, Arif R, Karck M, Szabo G. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2009;297:H125-H133.
9. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ, Chatham JC. Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart Circ Physiol 2007;293:H292-H298. (Pubitemid 47105084)
10. Baynes J, Murray DB. Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats. Oxid Med Cell Longev 2009;2: 328-334.
11. Van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, van der Velden J, Boer C, Ouwens DM, Diamant M. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 2009;8:39.
12. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004;13:11-19. (Pubitemid 38169461)
13. Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 2006;48:135-142. (Pubitemid 44691214)
14. Brussee V, Guo G, Dong Y, Cheng C, Martinez JA, Smith D, Glazner GW, Fernyhough P, Zochodne DW. Distal degenerative sensory neuropathy in a longterm type 2 diabetes rat model. Diabetes 2008;57:1664-1673.
15. Weiss JL, Frederiksen JW,Weisfeldt ML. Hemodynamic determinants of the timecourse of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
16. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol 2009;195:321-338.
17. Vora JP, Zimsen SM, Houghton DC, Anderson S. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 1996;7: 113-117. (Pubitemid 26067097)
18. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550. (Pubitemid 47614269)
19. Takeda Y, Sakata Y, Mano T, Ohtani T, Kamimura D, Tamaki S, Omori Y, Tsukamoto Y, Aizawa Y, Komuro I, Yamamoto K. Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 2011;13:664-669.
20. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004;102:223-241. (Pubitemid 38887694)
21. Van den Hurk K, Alssema M, Kamp O, Henry RM, Stehouwer CD, Diamant M, Boomsma F, Heine RJ, Nijpels G, Paulus WJ, Dekker JM. Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. Eur J Heart Fail 2010;12:958-965.
22. Forcheron F, Basset A, Abdallah P, Del Carmine P, Gadot N, Beylot M. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model-the Zucker diabetic rat. Cardiovasc Diabetol 2009;8:16.
23. Huang TH, Yang Q, Harada M, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways. J Cardiovasc Pharmacol 2005;46:856-862. (Pubitemid 44378261)
24. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342. (Pubitemid 350041472)
25. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56: 641-646. (Pubitemid 46348458)
26. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, Tschope C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008;103:319-327.
27. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155. (Pubitemid 350138497)
28. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, Tsuji T, Kohzuki H, Suga H, Taniguchi S, Takaki M. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 2002;282:H138-H148. (Pubitemid 34654144)
29. Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo D, Hoyt G, Robbins RC, Ashley EA, Wu J, Yang PC, Tsao PS. Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am J Physiol Heart Circ Physiol 2007;292:H2106-H2118. (Pubitemid 47084589)
30. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-1789. (Pubitemid 30118520)
31. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 1998;329:197-201. (Pubitemid 28022309)
32. Schrauwen P, Hoeks J, Hesselink MK. Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism Prog Lipid Res 2006;45:17-41. (Pubitemid 43170803)
33. Yu X, Burgess SC, Ge H, Wong KK, Nassem RH, Garry DJ, Sherry AD, Malloy CR, Berger JP, Li C. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc Natl Acad Sci USA 2005;102: 1767-1772. (Pubitemid 40209242)
34. Hernandez C, Candell-Riera J, Ciudin A, Francisco G, Aguade-Bruix S, Simo R. Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovasc Diabetol 2011;10:9.
35. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008;121:748-757.